NTRA News and Press, Natera Inc. From 08/03/23

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2023. Recent Strategic and Financial Highlights Generated total revenues of $261.4 million in the second quarter of 2023, compared to $198.2 ...

2023-08-02 17:35:58 ET Natera ( NASDAQ: NTRA ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, after market close. The consensus EPS Estimate is -$1.10 and the consensus Revenue Estimate is $241.53M (+21.9% Y/Y). Over the last 1 year, NTRA has b...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, Aug. 9 at 4:30 pm ET | 1:30 pm PT in Boston, MA. A live webcast and audio archive of t...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has filed a lawsuit in the North Carolina Federal District Court against NeoGenomics Labs, Inc. ("NeoGenomics") for infringement of Natera's U.S. Patent Nos. 11,519,035 and 11,530,454 by NeoGenomics&#...

Study to evaluate clinical utility of ctDNA-guided treatment escalation for CRC patients; results expected to read out in mid-2024 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the completion of enrollment to the randomized, double-blind phas...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2023, after the market close on Aug. 3, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET...

2023-07-17 17:38:24 ET Genetic testing company Natera ( NASDAQ: NTRA ) said on Monday that a Delaware court issued a decision in its favor in the false advertising lawsuit brought by rival CareDx ( NASDAQ: CDNA ). The Austin-based company said that the Delaware cour...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the United States District Court for the District of Delaware issued a decision in favor of Natera in the false advertising case brought by CareDx, Inc. In today’s decision, the Court reversed fin...

2023-07-09 18:15:18 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ), Establishment Labs ( NASDAQ: ESTA ), Arcus Biosciences ( NYSE: RCUS ) and BridgeBio Pharma ( NASDAQ: BBIO ) are four of BTIG's top picks for small and mid-cap healthcare stocks going into the lat...

2023-07-07 10:45:34 ET Update 10:45 AM EST: Adds comments from Craig Hallum Diagnostics firm Castle Biosciences ( NASDAQ: CSTL ) added ~41% in the morning hours Friday in a move attributed to an unexpected policy reversal regarding Medicare coverage for the company’s ...